Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Dewas, Claire V ^a   Maingon, Philippe ^a   Dalban, Cécile ^a   Petitfils, Aurélie ^a   Peignaux, Karine ^a   Truc, Gilles ^a   Martin, Etienne ^a   Khoury, Cédric ^a   Dewas, Sylvain ^b   Créhange, Gilles ^a  

^a Anticancer center Georges François Leclerc ^*  (France)

^b CENTRE OSCAR LAMBRET   (France)

Author keywords

3D CRT; Anal canal cancer; Chemoradiation; IMRT; Toxicity

Indexed keywords

CISPLATIN; FLUOROURACIL; MITOMYCIN;

ANUS CANCER; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; COLOSTOMY; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; RADIATION DOSE; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; THREE DIMENSIONAL CHEMORADIOTHERAPY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84870060423     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-201     Document Type: Article

References (20)

1. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996, 348:1049-1054. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin.
2. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M, Pierart M. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997, 15:2040-2049.
3. Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, Quivey J, Rotman M, Kerman H, Coia L, Murray K. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996, 14:2527-2539.
4. Bosset JF, Roelofsen F, Morgan DA, Budach V, Coucke P, Jager JJ, Van der Steen-Banasik E, Triviere N, Stuben G, Puyraveau M, Mercier M. Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer 2003, 39:45-51. 10.1016/S0959-8049(02)00377-5, 12504657.
5. Konski A, Garcia M, John M, Krieg R, Pinover W, Myerson R, Willett C. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys 2008, 72:114-118. 10.1016/j.ijrobp.2007.12.027, 2570743, 18472363.
6. Bazan JG, Hara W, Hsu A, Kunz PA, Ford J, Fisher GA, Welton ML, Shelton A, Kapp DS, Koong AC, et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 2011, 117:3342-3351. 10.1002/cncr.25901, 21287530.
7. Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Houry S, Gallot D, Parc R, Huang R, Qu SH, Huart J, et al. Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int J Radiat Oncol Biol Phys 2003, 56:1259-1273. 10.1016/S0360-3016(03)00417-6, 12873670.
8. Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol 2010, 28:5061-5066. 10.1200/JCO.2010.29.1351, 3018356, 20956625.
9. Constantinou EC, Daly W, Fung CY, Willett CG, Kaufman DS, DeLaney TF. Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys 1997, 39:651-657. 10.1016/S0360-3016(97)00329-5, 9336145.
10. Meyer A, Meier Zu Eissen J, Karstens JH, Bremer M. Chemoradiotherapy in patients with anal cancer: impact of length of unplanned treatment interruption on outcome. Acta Oncol 2006, 45:728-735. 10.1080/02841860600726729, 16938816.
11. Menkarios C, Azria D, Laliberte B, Moscardo CL, Gourgou S, Lemanski C, Dubois JB, Ailleres N, Fenoglietto P. Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol 2007, 2:41. 10.1186/1748-717X-2-41, 2204019, 18005443.
12. Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2005, 63:354-361. 10.1016/j.ijrobp.2005.02.030, 16168830.
13. Pepek JM, Willett CG, Wu QJ, Yoo S, Clough RW, Czito BG. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys 2010, 78:1413-1419. 10.1016/j.ijrobp.2009.09.046, 20231064.
14. Salama JK, Mell LK, Schomas DA, Miller RC, Devisetty K, Jani AB, Mundt AJ, Roeske JC, Liauw SL, Chmura SJ. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007, 25:4581-4586. 10.1200/JCO.2007.12.0170, 17925552.
15. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008, 299:1914-1921.
16. Matzinger O, Roelofsen F, Mineur L, Koswig S, Van Der Steen-Banasik EM, Van Houtte P, Haustermans K, Radosevic-Jelic L, Mueller RP, Maingon P, et al. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer 2009, 45:2782-2791. 10.1016/j.ejca.2009.06.020, 19643599.
17. Hodges JC, Das P, Eng C, Reish AG, Beddar AS, Delclos ME, Krishnan S, Crane CH. Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. Int J Radiat Oncol Biol Phys 2009, 75:791-794. 10.1016/j.ijrobp.2008.11.021, 19231109.
18. Kachnic LA, Winter KA, Myerson R, Goodyear M, Willins J, Esthappan J, Haddock M, Rotman M, Parikh P, Willett C. RTOG 0529: a phase II evaluation of dose-painted IMRT in combination with 5-Fluorouracil and Mitomycin-C for reduction of acute morbidity in carcinoma of the anal canal. 51st ASTRO Annual Meeting Chicago 2009, PS5.
19. Kachnic LA, Winter KA, Myerson R, Goodyear M, Willins J, Esthappan J, Haddock M, Rotman M, Parikh P, Willett C. Two year outcomes of RTOG 0529: a phase II evaluation of dose-painted IMRT in combination with 5FU and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. ASCO Annual Meeting; Chicago 2011, Abstr. 368.
20. Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL, Willins JD, Ryan DP, Hong TS. Dose-painted Intensity-modulated Radiation Therapy for Anal Cancer: A Multi-institutional Report of Acute Toxicity and Response to Therapy. Int J Radiat Oncol Biol Phys 2012, 82:153-158. 10.1016/j.ijrobp.2010.09.030, 21095071.